Certara, Inc.

Equities

CERT

US15687V1098

Software

Market Closed - Nasdaq 04:00:00 2024-03-27 pm EDT 5-day change 1st Jan Change
17.62 USD +2.68% Intraday chart for Certara, Inc. -0.23% +0.17%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Transcript : Certara, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:05 PM
UBS Raises Certara Price Target to $20 From $17, Maintains Neutral Rating MT
Transcript : Certara, Inc., Q4 2023 Earnings Call, Feb 29, 2024
Certera Adjusted EPS Declines, Revenue Climbs; Shares Fall After Hours MT
Certara, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Certara, Inc. Provides Earnings Guidance for the Year 2024 CI
Certara, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Earnings Flash (CERT) CERTARA Posts Q4 EPS $0.09, vs. Street Est of $0.11 MT
Earnings Flash (CERT) CERTARA Reports Q4 Revenue $88M, vs. Street Est of $86.7M MT
Leerink Partners Initiates Certara at Market Perform Rating With $19 Price Target MT
Barclays Adjusts Price Target on Certara to $18 From $16, Maintains Equal-Weight Rating MT
Certara Acquires Applied BioMath to Expand Biosimulation Capabilities MT
Certara, Inc. (NasdaqGS : CERT) acquired Applied BioMath, LLC for $36.6 million. CI
UBS Initiates Coverage on Certara With Neutral Rating, $17 Price Target MT
KeyBanc Initiates Certara at Sector Weight, Sees Current Valuation as 'Fair Given The More Muted End Markets' MT
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Certara Launches New Biopharmaceutics Software MT
Certara, Inc. Announces the Introduction of Simcyp Biopharmaceutics Software CI
Certara Seeks Acquisitions CI
Transcript : Certara, Inc. Presents at Stephens Annual Investment Conference | NASH 2023, Nov-15-2023 02:00 PM
Certara Q3 Adjusted Earnings, Revenue Increase; Reiterates Annual Guidance MT
Transcript : Certara, Inc., Q3 2023 Earnings Call, Nov 08, 2023
Certara, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (CERT) CERTARA Posts Q3 Revenue $85.6M, vs. Street Est of $86.2M MT
Earnings Flash (CERT) CERTARA Reports Q3 EPS $0.11, vs. Street Est of $0.11 MT
Chart Certara, Inc.
More charts
Certara, Inc. is a provider of biosimulation software and technology-enabled services. The Company is focused on producing medicines for patients using biosimulation software, technology, and services to transform traditional drug discovery and development. The Company builds its biosimulation technology on the first principles of biology, chemistry, and pharmacology with mathematical algorithms that model how medicines and diseases behave in the body. It offers an integrated, end-to-end platform for its clients, including various biopharmaceutical companies, academic institutions, and regulatory agencies across 62 countries. It also provides an artificial intelligence-powered platform for organizations to integrate and analyze content across their entire enterprise data landscape. It has operations in the United States, Australia, Canada, China, France, Germany, India, Italy, Japan, Luxembourg, Netherlands, Philippines, Poland, Portugal, Spain, Switzerland and the United Kingdom.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
11
Last Close Price
17.62 USD
Average target price
19.38 USD
Spread / Average Target
+9.98%
Consensus